Overview

A Phase 1, Open-Label, Single-photon Emission Computed Tomography (SPECT) Study to Evaluate Serotonin and Dopamine Transporter Occupancy After Multiple Dose Administration of SEP-228432 to Achieve Steady State in Healthy Subjects

Status:
Completed

Trial end date:
2012-05-01

Target enrollment:

Participant gender:

Summary

This is an open-label study investigating the relationship between SEP-228432 and SEP-228431 (the active metabolite of SEP-228432) plasma concentrations, SERT occupancy, and DAT occupancy, both measured by SPECT imaging.

Phase:

Phase 1

Details

Lead Sponsor:

Sunovion

Treatments:

Dopamine
Serotonin